

### REMARKS


Claims 1-14 are now pending for the Examiner's consideration.

**The restriction requirement set forth in the 2/23/2006 Office Action:**

On pages 2 of the Office Action of 2/23/2006, the Examiner required that the Applicants elect one group from Groups I to III wherein Group I consists of claims 1 to 4, Group II consists of claims 5 to 9 and Group III consists of claims 10-14. The Examiner further required that one single species be elected and that all claims that read upon the selected single species be listed, as set forth on page 3 to 4 of the Office Action.

**Applicants' election:**

Applicants herein elect Group I, which consists of claims 1 to 4. Applicants further elect species 8-fluoro-4-cyclohexylamino-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one, which is the third compound claimed in claim 4 of the application. The structure of this compound is the following:




Claims of Group I that read on this elected species are: claims 1 to 4.

If any fees other than those provided herein are due in connection with this response, please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: March 16, 2006

  
Ye Hua  
Attorney For Applicants  
Registration No. 53,042

**Pfizer Inc. Patent Department**  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-3020  
Fax: (858) 678-8233